The FDA has chosen Dr Vinay Prasad, a professor at UCSF, to lead its Center for Biologics Evaluation and Research.

Robert F. Kennedy Jr.'s "make America healthy again" is basically Lysenko 2.0. It's come to the NIH and is destroying the crown jewel of US biomedical research with ideology and cronyism.

Within Novo Nordisk's comprehensive business update to investors, attention latched onto early data for an oral obesity therapy that outperformed the company’s big-selling GLP-1 agonist Wegovy ...

As December 2022 closed out, Pfizer announced positive top-line results from its phase 3 BENEGENE-2 study evaluating fidanacogene elaparvovec (SPK-9001), its investigational gene therapy for ...

Bristol-Myers Squibb's Celgene unit has clearly been impressed by progress in its four-year-old alliance with Evotec on protein degradation. It's just paid $200 million to extend the partnership ...

ChatGPT has already made waves and has been deployed to write codes, new poems, songs, recipes, and whatnot. Language models that use transformer-based architectures, such as GPT (Generative Pre ...

An antibody-drug conjugate (ADC) that GSK licensed from China's Hansoh Pharma in a $1.7 billion deal last year has been given breakthrough status by the FDA. The coveted designation for GSK5764227 ...

Vinay Prasad will replace Marks as CBER director Trump's budget would be "catastrophic" for federal R&D Pharma still in waiting mode after UK-US trade agreement ...

Sanofi says that its experimental drug amlitelimab has the potential to become a ‘best-in-class’ maintenance therapy for atopic dermatitis (AD) after reporting new phase 2b data. The latest ...

The first biosimilars of AstraZeneca/Alexion's blockbuster complement C5 inhibitor Soliris have been launched in the US at a discount to the brand. Both Amgen's Bkemv and Teva/Samsung Bioepis ...

These have been dark days for the global economy, and the short-term prospects for the pharmaceutical industry look uncertain. The industry is currently undergoing change and restructuring on an ...

Novartis has reached an agreement to take control of Kate Therapeutics, a developer of gene therapies for inherited neuromuscular diseases, including Duchenne muscular dystrophy (DMD). The ...